Florida is currently home to 3829 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2025
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: H3 K27M, Glioma
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Recruiting
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: USOR Florida Cancer Specialists South, Fort Myers, Florida
Conditions: Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Triple Negative Breast Cancer, High Grade Epithelial Ovarian Cancer, Breast Adenocarcinoma, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Serous Ovarian Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Platinum-resistant Ovarian Cancer (PROC), Primary Refractory Ovarian Cancer, Uterine Cancer
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in grou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Tampa General Hospital /ID# 246748, Tampa, Florida
Conditions: Non-Hodgkin Lymphoma
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Recruiting
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Blood & Marrow Transplant Center, Florida Hospital Medical Group, Orlando, Florida
Conditions: Multiple Myeloma
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/07/2025
Locations: Synergy Healthcare, Bradenton, Florida
Conditions: Migraine
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Recruiting
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida
Conditions: Metastatic Prostate Cancer
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
Recruiting
This is an open-label phase 1 study with an escalation part and an expansion part.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/07/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Advanced Liver Cancer
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/07/2025
Locations: South Florida Research Phase I-IV, Inc, Miami Springs, Florida
Conditions: Acute Treatment of Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/07/2025
Locations: Topaz Clinical Research, Inc., Apopka, Florida
Conditions: Pediatric Migraine
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/07/2025
Locations: University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
Recruiting
This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from this study may help researchers better understand the relation between cell response and anti-HER2 therapies.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Breast Adenocarcinoma, HER2-Positive Breast Carcinoma
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
Recruiting
The purpose of this study is to determine if the dose of radiation therapy that is effective in producing a treatment response, delivered over a shorter treatment period, is a safe approach that causes few or mild side effects in women with newly diagnosed breast cancer or DCIS who have had a lumpectomy procedure.
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
07/07/2025
Locations: Baptist Alliance Miami Cancer Institute, Miami, Florida
Conditions: Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast, DCIS, DCIS Grade 1, DCIS Grade 2, Breast Cancer